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ARTICLE
                                        Merkel cell carcinoma is a rare but aggressive skin cancer of neu-
roendocrine origin (  1  ). The known risk factors for Merkel cell 
carcinoma include sun exposure, age more than 50 years, and im-
mune suppression (  2  ). The recent discovery of a novel polyomavi-
rus, Merkel cell polyomavirus (MCPyV), in approximately 75% of 
Merkel cell tumor tissues (  3  ) has led to the hypothesis that it is an 
etiologic agent for Merkel cell carcinoma. This hypothesis is bio-
logically plausible because other members of the polyomavirus 
family have been shown to cause tumors in animals (  4  ), and the T 
(tumor) antigen gene products, which inhibit the function of the 
retinoblastoma and p53 tumor suppressor proteins, are expressed 
in Merkel cell cancers (  5  ). Importantly, although the large T 
antigen is often mutated in the cancers, the retinoblastoma 
protein-binding domain and the conserved region 1 domain, 
which are essential regions for cell transformation, are preserved in 
Merkel cell carcinoma (  5  ). It is quite premature, however, to con-
clude that MCPyV causes Merkel cell carcinoma when so little is 
known about the natural history or the prevalence of the virus in 
the general population. 
  There are ﬁ  ve known members of the polyomavirus family for 
which humans are the primary host. BK virus (BKV) and JC virus 
(JCV) were discovered in the 1970s (  6  ,  7  ), and WU polyomavirus 
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     Background     Merkel cell polyomavirus (MCPyV) has been detected in approximately 75% of patients with the rare skin 
cancer Merkel cell carcinoma. We investigated the prevalence of antibodies against MCPyV in the general 
population and the association between these antibodies and Merkel cell carcinoma.   
     Methods     Multiplex antibody-binding assays were used to assess levels of antibodies against polyomaviruses in 
plasma. MCPyV VP1 antibody levels were determined in plasma from 41 patients with Merkel cell carci-
noma and 76 matched control subjects. MCPyV DNA was detected in tumor tissue specimens by quanti-
tative polymerase chain reaction. Seroprevalence of polyomavirus-specific antibodies was determined in 
451 control subjects. MCPyV strain  –  specific antibody recognition was investigated by replacing coding 
sequences from MCPyV strain 350 with those from MCPyV strain w162.   
     Results     We found that 36 (88%) of 41 patients with Merkel cell carcinoma carried antibodies against VP1 from 
MCPyV w162 compared with 40 (53%) of the 76 control subjects (odds ratio adjusted for age and sex = 6.6, 
95% confidence interval [CI] = 2.3 to 18.8). MCPyV DNA was detectable in 24 (77%) of the 31 Merkel cell 
carcinoma tumors available, with 22 (92%) of these 24 patients also carrying antibodies against MCPyV. 
Among 451 control subjects from the general population, prevalence of antibodies against human polyoma-
viruses was 92% (95% CI = 89% to 94%) for BK virus, 45% (95% CI = 40% to 50%) for JC virus, 98% (95% 
CI = 96% to 99%) for WU polyomavirus, 90% (95% CI = 87% to 93%) for KI polyomavirus, and 59% (95% CI = 
55% to 64%) for MCPyV. Few case patients had reactivity against MCPyV strain 350; however, indistin-
guishable reactivities were found with VP1 from strain 350 carrying a double mutation (residues 288 
and 316) and VP1 from strain w162.   
     Conclusion     Infection with MCPyV is common in the general population. MCPyV, but not other human polyomaviruses, 
appears to be associated with Merkel cell carcinoma.   
       J Natl Cancer Inst 2009;101:  1510    –    1522     jnci.oxfordjournals.org    JNCI | Articles 1511
(WUPyV) and KI polyomavirus (KIPyV) were identified in 
respiratory infections in 2007 (  8  ,  9  ). Infections with BKV and JCV 
are common, usually acquired in childhood, and persist throughout 
adulthood. Earlier studies of the humoral response to BKV and 
JCV used hemagglutination inhibition assays, whereas more recent 
studies have used enzyme-linked immunosorbent assays to detect 
antibodies against the major capsid proteins (VP1s) of each type 
(  10    –    12  ). Antibodies against BKV have been detected in 80%  –  90% 
of adults, and antibodies against JCV have been detected in 40%  –
  60% of adults (  13  ). There has been only one previous report on the 
prevalence of antibodies against WUPyV and against KIPyV (  14  ). 
Humoral responses to human polyomaviruses are generally type 
speciﬁ  c; however, some antibody cross-reactivity has been reported 
between simian virus 40 VP1  –  speciﬁ  c antibodies and BKV VP1 and 
between BKV VP1  –  speciﬁ  c antibodies and simian virus 40 (  15  ). 
  To determine whether an association exists between MCPyV-
speciﬁ  c antibodies and Merkel cell carcinoma, it was important to 
evaluate the potential for antibody cross-reactivity against VP1 
proteins from other human polyomaviruses. Waterboer et al. (  16  ) 
developed a multiplex serological assay that uses glutathione 
S-transferase (GST)  –  VP1 fusion proteins tethered to spectrophoto-
metrically distinguishable colored microbeads. We adapted this 
method to study the antibody response against the ﬁ  ve polyomavi-
ruses that infect humans and used it in two analyses. The ﬁ  rst analysis 
was a case  –  control study designed to test the hypothesis that case 
patients with Merkel cell carcinoma are more likely than control 
subjects to carry antibodies against MCPyV VP1. The second analysis 
was a population-based study designed to determine the prevalence of 
polyomavirus-speciﬁ  c antibodies in the general population. 
    Subjects and Methods 
    Study Subjects and Plasma, Serum, and Tumor Specimens 
  Merkel cell carcinoma plasma and serum samples were from 
the Merkel Cell Carcinoma Repository of Patient Data and 
Specimens, Fred Hutchinson Cancer Research Center, University 
of Washington. Consecutive patients (n = 41) who agreed to partic-
ipate and gave informed consent were enrolled between January 1, 
2008, and August 31, 2008, and are the case patients for this analysis. 
Case patients ranged in age from 42 to 86 years at diagnosis and 
included 27 men and 14 women. Control subjects for the Merkel cell 
carcinoma case  –  control study, referred to as control group 1, were 
randomly selected from control subjects with available specimens 
(serum and plasma) in a previously reported case  –    control study (  17  ) 
at the Fred Hutchinson Cancer Research Center. Control group 1 
was frequency matched to case patients by age and sex and included 
51 men and 25 women, for a total of 76 subjects. All serum and 
plasma specimens were stored at   –  70°C until testing. Tissue samples 
of Merkel cell carcinomas that were tested for Merkel cell polyoma-
virus DNA were obtained as excess surgical tissue or extracted from 
archival formalin-fixed paraffin-embedded blocks, when the mate-
rials were available and the patient had given consent. All specimens 
contained at least 50% tumor cells as estimated by histology. 
  A second set of 451 women were studied as population-based 
control subjects and referred to as control group 2. These women 
ranged in age from 24 to 77 years and had previously participated 
in a study of anogenital cancer (  17  ) to explore the age-speciﬁ  c 
prevalence and potential role of sexual transmission of polyomavi-
ruses compared with human papillomavirus type 16 (HPV-16). 
HPV-16 serology from these women has been reported previously 
(  17  ,  18  ). Control group 2 was selected from the general population 
as previously described (  17  ,  18  ). Brieﬂ   y, control subjects were 
women residing in King, Pierce, and Snohomish counties, which 
constitute metropolitan Seattle, who were recruited by use of 
random-digit dialing and matched to the age of men and women 
with various cancers. Written informed consent was obtained and 
all procedures and protocols were approved by Institutional 
Review Boards of the Fred Hutchinson Cancer Research Center 
and the University of Washington.   
    Plasmids and Cloning, Preparation of Fusion Proteins, 
Immunoblot Analysis, and Site-Directed Mutagenesis 
  Chemicals were purchased from Sigma (Sigma Chemical, St Louis, 
MO) unless otherwise noted. The DNA constructs pGEX4t3.tag, 
pGEX.BKV, and pGEX.JCV were provided by Dr Michael 
Pawlita (German Cancer Research Center, Heidelberg, Germany) 
(  16  ). pGEX.BKV and pGEX.JCV were used to produce fusion 
proteins between GST and the VP1 proteins from BKV and 
from JCV, respectively. Any sequence inserted in-frame into the 
  Bam  HI  –    Sal  I sites of the pGEX4t3.tag plasmid created fusion 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  Approximately 75% of patients with the rare skin cancer Merkel cell 
carcinoma appear to carry Merkel cell polyomavirus (MCPyV).   
    Study design 
  A retrospective case  –  control study was used to study levels of 
antibodies against polyomaviruses in plasma from 41 patients 
with Merkel cell carcinoma and 76 matched control subjects. 
Seroprevalence of polyomavirus-specific antibodies was deter-
mined in another 451 control subjects, who represented the gen-
eral population. MCPyV DNA was detected in tumor tissue 
specimens.   
    Contribution 
  The authors found that 36 (88%) patients with Merkel cell carci-
noma carried antibodies against MCPyV compared with 40 (53%) 
control subjects. MCPyV DNA was detectable in 24 (77%) of the 31 
Merkel cell carcinoma tumors available, with 22 (92%) of these 
patients also carrying antibodies against MCPyV. Among 451 con-
trol subjects from the general population, prevalence of antibodies 
against the five human polyomaviruses was 92% for BK virus, 45% 
for JC virus, 98% for WU polyomavirus, 90% for KI polyomavirus, 
and 59% for MCPyV.   
    Implications 
  Although infection with MCPyV is common in the general popula-
tion, MCPyV, but not the other four human polyomaviruses, ap-
pears to be associated with Merkel cell carcinoma.   
    Limitations 
  The case  –  control study was small. Study subjects were primarily 
white, so that results may not be generalizable. There is no “gold 
standard” for determining MCPyV positive or negative status. 
    From the Editors       
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proteins with GST on the amino terminus and an 11-amino acid 
“Tag” epitope (so called because it targets a region of the simian 
virus 40 large T antigen) on the carboxyl terminus (  19  ), so that 
fusion proteins could be recognized by anti-Tag antibodies (  20  ). 
The MCPyV strain 350 expression plasmid (pGEX.MCPyV350) 
was provided by Dr Robert Garcea (University of Colorado, 
Boulder, CO) (  14  ). Dr Tobias Allander (Karolinska Institute, 
Stockholm, Sweden) and Dr David Wang (Washington University, 
St Louis, MO) provided plasmids containing KIPyV (pGEM-
KIPyVP1-2) and WUPyV (pENTR-WUPy) sequences, respec-
tively (  8  ,  9  ). The VP1 open reading frames of KIPyV, WUPyV, 
and MCPyV (from tumor w162) were cloned into the modified 
pGEX4t3 plasmid after removal of the JCV VP1 sequence from 
pGEX.JCV by digestion with   Bam  HI and   Sal  I and gel isolation of 
the vector. Primers (listed in     Supplementary     Table     1    , available 
online) were used to amplify the VP1 sequences by polymerase 
chain reaction (PCR) performed with pfu Ultra (Stratagene, La 
Jolla, CA) for KIPyV and WUPyV, with reaction conditions of 
2 minutes at 94°C followed by 30 cycles of 94°C for 15 seconds, 
55°C for 30 seconds, and 68°C for 90 seconds; or AmpliTaq Gold 
(Applied Biosystems, Foster City, CA) for MCPyV, with reaction 
conditions of 5 minutes at 95°C followed by 40 cycles of 95°C for 
15 seconds, 55°C for 30 seconds, and 72°C for 90 seconds. All 
products were subcloned into the CR Blunt II Topo vector 
(Invitrogen Corp, Carlsbad, CA) following the manufacturer  ’  s 
protocol. Clones containing a VP1 insert of the expected size were 
digested with   Bam  HI and   Sal  I and subcloned into the gel-purified 
pGEX4t3.tag plasmid. All pGEX clones were verified by BigDye 
sequencing (Applied Biosystems), and sequences were aligned by 
use of Vector NTI (Invitrogen). Sequences were compared by use 
of the ClustalW program (    http  ://  align  .  genome  .  jp  /  ). The MCPyV 
w162 VP1 sequence (GenBank accession No. FJ392560) was pre-
dicted to express a protein that was identical to the MCPyV 339 
VP1 sequence (GenBank accession No. EU375804), except at 
residue 422, which was mutated because the primers used for 
cloning were based on the MCPyV 350 VP1 sequence.         
  We sequenced seven additional Merkel cell carcinomas from 
the Merkel Cell Carcinoma Repository of Patient Data and 
Specimens, Fred Hutchinson Cancer Research Center, University 
of Washington. Partial VP1 sequences were obtained by ampliﬁ  -
cation by PCR, with reaction conditions of 5 minutes at 95°C 
followed by 40 cycles of 95°C for 30 seconds, 58°C for 30 seconds, 
and 72°C for 90 seconds and the sequencing primers listed in 
    Supplementary     Table     1     (available online). PCR products were 
electrophoresed on a 1% agarose gel to conﬁ  rm size and submitted 
to Functional Biosciences, Inc (Madison, WI) for ExoSAP cleanup 
(ie, enzyme-mediated removal of remaining primers, other single-
stranded DNAs, and leftover deoxynucleoside triphosphates) and 
bidirectional sequencing to determine amino acid sequences and to 
analyze polymorphisms at positions 185, 288, 316, and 366. 
  Polyomavirus VP1 fusion proteins were expressed in Rosetta 
  Escherichia coli   (EMD Biosciences Inc, La Jolla, CA) by induction 
of a 1-L culture (optical density at 600 nm = 0.5) with 0.25 mM 
isopropyl     -  d  -1-thiogalactopyranoside, and bacteria were allowed 
to grow overnight at room temperature. Cells were lysed by two 
passes through a Microﬂ   uidizer (model M-110S; Microﬂ  uidics 
Corp, Newton, MA). Lysates were prepared as described by Sehr 
et al. (  21  ), diluted with an equal volume of glycerol (Fisher 
Scientiﬁ  c, Pittsburgh, PA), and stored at     20°C. 
  For immunoblot analysis, the bacterial lysates were diluted in 
sample buffer containing 100 mM dithiothreitol and 1% sodium 
dodecyl sulfate and heated to 100°C for 5 minutes, and 4   µ  g of 
lysate protein per lane was electrophoresed on 10% EZ-Run 
(Fisher Scientiﬁ   c, Fair Lawn, NJ) polyacrylamide gels in a 
HoeferVE mini-electrophoresis apparatus (Hoefer Inc, Holliston, 
MA). Proteins were transferred from the polyacrylamide gel to a 
nitrocellulose (NitroBind; Micron Separations Inc, Westboro, 
MA) membrane in a HoeferVE mini-electrotransfer apparatus (2.5 
hours at 300 mA in a buffer of 25 mM Tris base, 192 mM glycine, 
and 10% methanol), and the blot was blocked overnight with 1% 
nonfat dry milk in phosphate-buffered saline (PBS). VP1 expres-
sion in each bacterial lysate was conﬁ  rmed by immunoblotting 
with a monoclonal antibody against the epitope Tag by use of 
antibody-containing supernatant from the KT3 hybridoma cell 
line provided by Michael Pawlita and by use of multiplex serolog-
ical assays as described below. Immunoblot analysis was conducted 
by use of a Snap i.d. apparatus (Millipore Corp, Billerica, MA). 
KT3 supernatant (containing anti-Tag monoclonal antibodies) 
(20   µ  L) was diluted with 3 mL of PBS plus nonfat dry milk (0.5%) 
and the mixture was incubated with the blot for 10 minutes. The 
blot was washed three times with PBS  –  0.05% Tween 20 (Fisher 
Scientiﬁ  c), and 3 mL of PBS  –  0.5% nonfat dry milk containing 
1   µ  L of horseradish peroxidase linked to anti-murine IgG (Jackson 
ImmunoResearch Laboratories, West Grove, PA) was added and 
incubated with the blot for 10 minutes. The membrane was 
washed as described above and developed by use of Lumi-Light 
  Table 1    .       Antibody positivity to polyomaviruses in women in the general population (control group 2) by age group  *     
    Age, y No. in age group
No. positive (%)     
  BKV JCV WUPyV KIPyV MCPyV w162   
    <30 48 47 (97.9) 22 (45.8) 46 (95.8) 45 (93.8) 27 (56.9) 
  30  –  39 122 114 (93.4) 49 (40.2) 120 (98.4) 110 (90.2) 66 (54.3) 
  40  –  49 119 113 (95.0) 42 (35.3) 116 (97.5) 108 (90.8) 78 (65.7) 
  50  –  59 83 70 (84.3) 50 (60.2) 82 (98.8) 76 (91.6) 51 (60.9) 
  60  –  69 46 42 (91.3) 22 (47.8) 45 (97.8) 41 (89.1) 30 (65.8) 
    ≥  70 33 27 (81.8) 18 (54.5) 31 (93.9) 26 (78.8) 19 (57.8) 
    P    trend      †     .004 .04 .9 .2 .6   
    *     BKV = BK virus; JCV = JC virus; KIPyV = KI polyomavirus; MCPyV w162 = Merkel cell polyomavirus strain w162; WUPyV =WU polyomavirus.   
      †       The test for trend was a nonparametric two-sided test that is an extension of the Wilcoxon rank sum test.     jnci.oxfordjournals.org    JNCI | Articles 1513
reagents (Roche  –  Applied Biosystems, Indianapolis, IN) as described 
in the product protocol. 
  Site-directed mutagenesis was used to replace one, two, or 
three amino acids in the codon-modiﬁ   ed VP1 sequence from 
MCPyV strain 350 in the pGEX4t3 vector with the corresponding 
amino acids in VP1 from MCPyV strain w162. The codon- 
modiﬁ  ed sequence was used because the expression level of capsid 
proteins may depend on the match between the codon used and 
the tRNA that is available (  22  ). Mutagenesis was performed by 
amplifying plasmid DNA (pGEX__MCPyVw162) in two tubes 
each containing 5 ng of DNA and one of two complementary 
primers (    Supplementary     Table     1    , available online) encoding the 
sequence changes. After three cycles of PCR (pfu Ultra, 95°C for 
30 seconds, 55°C for 1 minute, and 68°C for 15 minutes), the tubes 
were combined, an additional 1   µ  L of polymerase was added, and 
20 additional PCR cycles were performed under the same condi-
tions. After ampliﬁ  cation,    Dpn  I restriction endonuclease was 
added (1   µ  L) and the mixture was incubated for 2 hours at 37°C to 
digest the input plasmid DNA. After digestion, the ampliﬁ  ed DNA 
was used to transform One Shot Top 10 cells (chemically compe-
tent   E coli  , Invitrogen). The bacteria were grown overnight at 37°C 
on LB agar plates containing carbenicillin at 50   µ  g/mL. The entire 
VP1 open reading frame from carbenicillin-resistant colonies was 
sequenced to identify clones with the desired sequence changes. 
To generate VP1 mutants that had more than one amino acid al-
teration, the changes were made sequentially by use of DNA that 
had one (or two) mutation(s) as the starting material to generate a 
sequence with two (or three) mutations. The mutations made were 
the replacement of histidine with asparagine at VP1 position 288 
(H288D), the replacement of isoleucine with arginine at position 
316 (I316R), and/or the replacement of asparagine with aspartic 
acid at position 366 (N366D). Although the MCPyV w162 VP1 
amino acid sequence also differs from that of MCPyV 350 VP1 at 
position 185, that residue was not modiﬁ  ed because it was not well 
conserved among the other polyomaviruses.   
    Multiplex Antibody-Binding and Quantitative Multiplex 
Antibody-Binding Assays 
    Preparation of Antigen-Coated Beads.             Polyomavirus VP1  –
  GST fusion proteins, GST, and the fusion protein containing L1 
protein from HPV-16 and GST were bound to specific bead sets 
according to the methods of Waterboer et al. (  16  ,  23  ). Briefly, 
polystyrene microspheres or beads containing a unique combina-
tion of fluorescent dyes (MiraiBio, South San Francisco, CA) were 
covalently coupled with glutathione-linked casein. The beads are 
light sensitive and so were protected from the light during all in-
cubations. The first experiment used VP1 fusion protein prepara-
tions (all in crude bacterial lysates) from the human polyomaviruses 
(BKV, JCV, WUPyV, and KIPyV as well as both MCPyV strains, 
w162 and 350) and a preparation of GST protein; a total of seven 
bead sets were included in this analysis. The second experiment 
used GST, the VP1 fusion proteins for the five human polyoma-
viruses (including MCPyV strain w162 but not MCPyV strain 
350), and GST  –  L1 from HPV-16 (which was included to investi-
gate potential associations between seropositivity to polyomavirus 
with age or number of sex partners) because the seroepidemiology 
of HPV-16 has been studied (  18  ); a total of seven bead sets for 
these seven proteins were included in this analysis. In the third 
experiment, which tested for reactivity against mutated MCPyV 
VP1 fusion proteins, the seven mutated VP1 proteins, wild-type 
VP1 fusion proteins from MCPyV strains w162 and 350, GST, 
and BKV VP1 fusion proteins were used; a total of 11 bead sets 
were included in this analysis. For all three experiments, 1 mg of 
a bacterial lysate containing a distinct fusion protein or GST was 
diluted to a final volume of 1 mL with PBS containing casein at 
1 mg/mL (PBS  –  casein) and incubated with a spectrophotometri-
cally distinct bead set that had previously been coupled with 
casein  –  glutathione for 1 hour at room temperature with moderate 
shaking (Thermo Scientific Barnstead Titer Plate Shaker; 
Barnstead International, Dubuque, IA). The number of beads (per 
set) used for each experiment varied and was calculated as 2750 
beads times the number of wells (equal to the total number of 
plasma samples, serum samples, and monoclonal antibodies) to be 
tested. Unbound antigens were removed by three washes with 0.5 
mL of PBS  –  casein and resuspended in the same buffer by three 
cycles of sonication followed by vigorous vortex mixing. Finally, 
all antigen-coated bead sets used in an experiment were combined 
and diluted in PBS  –  casein to a final concentration of 55    000 beads 
per milliliter for each bead set (ie, if seven bead sets were being 
used in an experiment, then 7 × 55    000 beads per mL = 385    000 
beads per mL would be used).   
    Pretreatment of Serum or Plasma.             To reduce nonspecific 
binding, human serum and plasma samples were incubated with 
blocking buffer before being incubated with antigen-coated beads. 
Each human serum or plasma sample (2   µ  L) was diluted 1:50 in 
blocking buffer (0.5% polyvinyl alcohol, 0.8% polyvinylpyrroli-
done, 0.025% CBS-K superblock [Chemicon International, 
Temedula, CA], and GST-containing bacterial lysate at 2 mg/mL 
in PBS  –  casein) in 96-well polypropylene plates (Fisher). Plates 
were incubated for 1 hour at room temperature with shaking. 
When monoclonal antibodies were used in this experiment, they 
were not pretreated with blocking buffer but were diluted in 
PBS  –  casein, 1:100 dilution for anti-Tag monoclonal antibodies 
and 1:500 dilution for anti-GST monoclonal antibodies.   
    Multiplex Antibody Binding Assay.             We transferred 50   µ  L of pre-
treated antibody-containing serum or plasma or 50   µ  L of dilute 
monoclonal antibodies from the polypropylene plate to the wells of 
a 96-well filter plate, which has a mesh backing to allow for repeated 
filtrations and incubations (Multiscreen   HTS  -BV      ; Millipore Corp, 
Bedford, MA). The antigen-coated bead mixture (containing all 
bead sets) (50   µ  L) was added to each well containing pretreated 
serum or plasma or diluted monoclonal antibodies. With the excep-
tion of the cross-sectional study in which serum from control group 
2 was studied, plates were incubated for 1 hour at room temperature 
with shaking. For the cross-sectional study, plates were incubated 
overnight at 4°C followed by a 1-hour incubation at room temper-
ature with shaking; the longer incubation time in this study was used 
to improve detection of HPV-16 L1 by human antibodies that were 
included in this assay. Wells were washed three times with 100   µ  L 
of PBS  –  casein. Either biotin-coupled anti-human IgG (KPL, 
Gaithersburg, MD) or biotin-coupled anti-mouse IgG (PerkinElmer 
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in PBS  –  casein and 50   µ  L was added per well. Plates were incubated 
for 30 minutes with shaking and the wells were washed as described 
above. Streptavidin coupled to phycoerythrin (Invitrogen; diluted 
1:1000 in PBS  –  casein) was added (50   µ  L per well) to detect biotin-
coupled bound antibodies. Plates were incubated for 30 minutes and 
the wells were washed three times in PBS  –  casein. After 100   µ  L of 
PBS  –  casein was added to each well, the amount of phycoerythrin 
bound to beads was determined on a BioPlex 200 Instrument 
(BioRad Laboratories, Hercules, CA) as a reflection of the amount 
of bound antibody and expressed as the median fluorescent inten-
sity. For each sample, the antigen-specific binding was obtained by 
subtracting the median fluorescent intensity for beads coated with 
GST alone from that for beads coated with each of the other fusion 
proteins.   
    Cut-point Determination.             Cut points for antibody positivity were 
selected by visual inspection of the distribution of MCPyV values 
among control subjects for that study. For the case  –  control study, 
the cut point for antibody positivity was a median fluorescent inten-
sity of more than 5000. To evaluate the robustness of the association 
between MCPyV antibody positivity and Merkel cell carcinoma, we 
used a sliding cut point. Statistically significant associations between 
MCPyV antibody positivity and Merkel cell carcinoma were 
observed for median fluorescent intensity values between   –  109 and 
29    062 (median fluorescent intensity values were corrected for back-
ground reactivity as measured by GST reactivity, which was sub-
tracted from the crude median fluorescent intensity value for each 
antigen, resulting occasionally in corrected median fluorescent in-
tensity values of less than 0). For the cross-sectional study, the cut 
point for antibody positivity was a median fluorescent intensity of 
more than 15    000. The cut point for HPV-16 antibodies was 820.25 
and was based on the upper quartile of median fluorescent intensity 
values from control subjects.   
    Normalization of Binding to Beads Coated With Mutated VP1 
Proteins.             To compare reactivity against mutated VP1 proteins 
with reactivity against wild-type VP1 proteins, the median fluores-
cent intensity (MFI) values from each plasma (ie, one well) were 
normalized as:
   [MFI(VP1 ) MFI(GST)]/[MFI(VP1 ) MFI(GST)],  wt i −−  
where VP1    i     is reactivity against MCPyV 350 VP1 or a mutated 
VP1, VP1  wt   is reactivity against wild-type MCPyV w162 VP1, and 
GST is reactivity against GST-coated beads. Normalized values 
from all plasma samples that were positive (ie, median ﬂ  uorescent 
intensity of >5000 against MCPyV w162 VP1) were averaged. 
This experiment was conducted twice with similar results.   
    Quantitative Multiplex Antibody Binding Assay.             Using a 1:100 
dilution of antibodies resulted in median fluorescent intensity values 
that were higher than the linear range of the assay for some samples. 
To ensure that some data points from each positive sample fell 
within the linear range of the assay, serial dilutions of each antibody-
containing sample (hybridoma supernatant, serum, or plasma) were 
made in blocking buffer. All other steps of the assay were the same 
as above, including a 1-hour incubation of bead mixture with serum, 
plasma, or monoclonal antibody. In one experiment, a single serum 
with strong reactivity against BKV, JCV, WUPyV, KIPyV, and 
MCPyV w162 from a control subject without Merkel cell carcinoma 
was diluted 1:50 in blocking buffer, followed by a series of five 1:5 
serial dilutions in wells of a 96-well polypropylene plate (final dilu-
tions when mixed 1:2 [vol/vol] with bead mixture = 1:100 to 
1:312    500). In another experiment, plasma samples from the case  – 
  control study (or anti-Tag monoclonal antibodies) were diluted 
1:166.5 in blocking buffer, followed by seven 1:3 serial dilutions in 
blocking buffer (final dilutions with antigen-coated bead mixture = 
1:300 to 1:729    000). The plates were incubated for 1 hour at room 
temperature with shaking. These pretreated samples were then 
transferred to 96-well filter plates, the appropriate antigen-coated 
beads were added, and all subsequent steps were conducted as 
described above for the multiplex antibody-binding assay with a 
1-hour incubation of antibodies with antigen-coated beads. 
  The antibody dilution producing one-half of the maximal 
binding (EC  50   value) was computed by use of median ﬂ  uorescent 
intensity values from the experiment with serial dilutions of plasma 
samples and the curve ﬁ   tting function in the Prism program 
(GraphPad Software Inc, La Jolla, CA), which also was used to pro-
duce all graphs. For each sample, the median ﬂ  uorescent intensity 
values and inverse natural logarithm of the plasma dilution were ﬁ  t 
to the sigmoidal dose  –  response (with variable slope) equation:
    §·
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where   y    0   is the lowest median ﬂ  uorescent intensity value,   a   is the 
highest median ﬂ  uorescent intensity value minus the lowest me-
dian ﬂ  uorescent intensity value,   x   is the natural logarithm of the 
antibody dilution,   x    0   is the natural logarithm of the plasma dilution 
at the EC  50   value, and   b   is the slope of curve. For the 11 plasma 
samples tested, the   R    2   was greater than .991 (95% conﬁ  dence 
interval [CI] = 0.987 to 0.995), indicating that this equation was an 
excellent ﬁ  t for these data. 
  To evaluate the reproducibility of this assay when serum vs 
plasma samples were used, the percentage of positive samples was 
compared between serum and plasma samples from each of the 75 
control subjects and 16 case patients who had both serum and 
plasma available. A monoclonal antibody against GST (B-14; 
Santa Cruz Biotechnology, Santa Cruz, CA) was used to verify 
expression of the MCPyV strain 350 VP1  –  GST fusion protein 
(which lacked the epitope tag). The results were identical for 73 
(97%) of 75 replicates among control subjects and all 16 replicates 
from case patients. Because there were fewer serum samples avail-
able for case patients and no statistical difference in the proportion 
positive by each test for control samples (57% and 55%), plasma 
samples were used for subsequent multiplex antibody assays.     
    Amplification of MCPyV DNA From Merkel Cell Carcinoma 
Tumor Tissue 
  DNA was extracted from paraffin-embedded Merkel cell carci-
noma tumor tissue of patients in the case  –  control study by use of a 
QIAamp DNA FFPE tissue kit (Qiagen, Valencia, CA) or from 
fresh Merkel cell tumor tissue with ALLprep DNA/RNA kits by 
the manufacturers  ’   instructions. Tumor samples from 10 patients jnci.oxfordjournals.org    JNCI | Articles 1515
were not available for DNA extraction. Quantitative PCR amplifi-
cation of MCPyV DNA from tumor samples from 31 case patients 
with Merkel cell carcinoma was performed as previously described 
(  24  ). Briefly, two primer sets were used that targeted MCPyV, but 
not the other human polyomaviruses, and another set of primers 
were used that targeted the   TPO   gene for comparison (for primer 
sequences, see     Supplementary     Table     1    , available online). Reactions 
were conducted in triplicate along with a negative control sample.   
    Statistical Methods 
  The prevalence of polyomavirus antibodies by age and number of 
sexual partners were compared by use of trend tests to investigate 
changes in the prevalence of these factors in case patients and con-
trol subjects. Relative risk of Merkel cell cancer was approximated 
by use of odds ratios (ORs) and 95% confidence intervals derived 
from logistic regression models. All odds ratios were adjusted for 
the matching factors, age, and sex. 
  Two-sided   t   tests were used to compare average median ﬂ  uores-
cent intensity values across groups for all analyses. Statistical signif-
icance of trends across ordered groups in control group 2 was tested 
by use of a nonparametric test for trend that is an extension of the 
Wilcoxon rank sum test with a correction for ties (  25  ). Virus-speciﬁ  c 
seropositivity rates were compared across control groups (limiting 
control group 1 to women to match the sex of control group 2) by 
use of       2   tests. A McNemar test was used to examine the difference 
between plasma and serum samples and a Fisher exact test was used 
to compare antibody results to DNA results from case patients. A 
Mann  –  Whitney test was used to compare EC  50   values between case 
patients and control subjects. All statistical tests were two-sided, with 
a   P   value less than .05 being considered statistically signiﬁ  cant.     
    Results 
    Prevalence of Antibodies Against Polyomaviruses in Case 
Patients With Merkel Cell Carcinoma and Control Subjects 
  We assessed levels of antibodies against the five known human 
polyomaviruses (BKV, JCV, WUPyV, KIPyV, and MCPyV) by 
use of a multiplex antibody-binding assay and recombinant 
proteins containing VP1 from these five human polyomaviruses 
fused to GST. To determine whether human antibody responses 
were restricted to certain MCPyV strains, we constructed VP1 
fusion proteins from MCPyV strains w162 and 350, whose se-
quences differ at four amino acid positions. For the first experi-
ment, we used plasma samples from 41 case patients with Merkel 
cell carcinoma and from 76 age- and sex-matched population-
based control subjects. Across samples from control subjects, levels 
of antibodies against MCPyV strain w162 appeared dichotomous 
(  Figure 1  ). By use of a cut point of 5000 median fluorescent inten-
sity units to define antibody positivity (  Figure 1, A  ), 40 (53%) of 
the 76 control subjects carried antibodies against MCPyV w162 
compared with 36 (88%) of the 41 case patients with Merkel cell 
carcinoma (OR adjusted for age and sex = 6.6, 95% CI = 2.3 to 
18.8) (  Figure 1, B and C  ). Among the 76 control subjects in control 
group 1, 58 (76%) carried antibodies against BKV, 34 (45%) 
against JCV, 71 (93%) against WUPyV, and 58 (76%) against 
KIPyV. No associations were observed between antibody posi-
tivity against BKV, JCV, WUPyV, or KIPyV and Merkel cell 
carcinoma case status (  Figure 1, C  ), and no associations were 
observed between MCPyV w162 VP1 reactivity and the reactivity 
against VP1 proteins from any of these four polyomaviruses. 
Linear regression analyses also detected no correlation between 
reactivity against MCPyV w162 VP1 and the reactivity against 
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    Figure 1    .       Reactivity against the ﬁ  ve human polyomaviruses in serum 
from 41 case patients with Merkel cell carcinoma and from 76 age- and 
sex-matched population-based control subjects in control group 1.   A  ) 
Reactivity of plasma samples from all 76 control subjects in control 
group 1 against major capsid proteins (VP1 proteins) from ﬁ  ve polyo-
maviruses: BK virus (BKV), JC virus (JCV), WU polyomavirus (WUPyV), 
KI polyomavirus (KIPyV), and Merkel cell carcinoma polyomavirus 
(MCPyV strains 350 and w162). Antibody reactivity speciﬁ  c for polyo-
mavirus VP1 proteins was examined by use of a multiplex antibody-
binding assay. Each   circle   represents the median ﬂ  uorescent intensity 
(MFI) value from a plasma sample against the fusion protein indicated. 
  B  ) Reactivity of plasma samples from 41 case patients with Merkel cell 
carcinoma against VP1 proteins from the ﬁ  ve polyomaviruses. These 
plasma samples were tested as described for the control subjects.   C  ) 
Percentage of seropositive case patients and control subjects. 
Percentages of subjects in panels   A   and   B   who were seropositive for 
antibodies against each polyomavirus were determined by use of a cut 
point for seropositivity of more than 5000 MFI units.         1516   Articles | JNCI  Vol. 101, Issue 21  |  November 4, 2009
VP1 proteins from BKV, JCV, WUPyV, or KIPyV (range of   r   
2   
values = .001  –  .065) (  Figure 2  ).                   
    Association of MCPyV Viral DNA in Merkel Cell 
Carcinomas With MCPyV Antibody Positivity 
  We investigated whether MCPyV viral DNA could be detected in 
Merkel cell tumors by quantitative PCR and investigated the relation-
ship between positivity for MCPyV w162 VP1 antibody and posi-
tivity for viral DNA. Tumor tissue was available from 31 of the 41 
case patients with Merkel cell carcinoma. We found that 24 (77%) of 
these 31 tumors contained MCPyV DNA. Among the 24 case 
patients who were positive for MCPyV DNA, 22 (92%) were positive 
for MCPyV w162 antibodies. Among the seven case patients who 
were negative for MCPyV DNA, all were positive for MCPyV w162 
antibody. Thus, the proportion of case patients with MCPyV anti-
bodies was high regardless of the MCPyV DNA status of the tumor.   
    Identification of Amino Acids Responsible for Low 
Antibody Binding to MCPyV Strain 350 
  Although frequent and strong antibody reactivity was observed 
against the VP1 from MCPyV strain w162 among the serum sam-
ples from the subjects in the case  –  control study, little activity was 
found against the VP1 from MCPyV strain 350 (  Figure 1  ). In a 
serum sample with strong MCPyV w162 reactivity, the level of 
antibodies against VP1 from MCPyV w162 was 6  –  14 times higher 
than those of antibodies against VP1 protein from BKV, JCV, 
WUPyV, or KIPyV; however, this serum had no reactivity against 
the VP1 from MCPyV strain 350 (  Figure 3  ). Low reactivity against 
MCPyV was not explained by lower expression of the MCPyV 350 
fusion protein (    Supplementary     Figure     1  ,   B    , available online). 
Sequences of the VP1 proteins from MCPyV strains w162 and 350 
differ by four amino acids. To determine which, if any, of these 
residues may be responsible for the difference in antibody reactivity, 
we used site-directed mutagenesis to create a series of recombinant 
VP1 proteins in which one, two, or three amino acids in the VP1 
sequence of strain 350 were replaced with corresponding amino 
acids in the VP1 sequence of strain w162 (  Figure 4, A  ). We selected 
residues 288, 316, and 366 because they are evolutionarily conserved 
among human polyomaviruses under the hypothesis that mutations 
in conserved regions would disrupt the correct folding of the VP1 
proteins. The mutations introduced were a histidine to aspartic acid 
change at position 288 (H288D), an isoleucine to arginine change at 
position 316 (I316R), and/or an asparagine to aspartic acid change 
at position 366 (N366D). Residue 185 also differed between se-
quences of MCPyV strains 350 and w162 but it was not conserved 
among the other polyomaviruses and so not investigated further. To 
determine which amino acids in the VP1 from MCPyV w162 were 
responsible for reactivity in human plasma, plasma samples from 26 
subjects (12 case patients with Merkel cell carcinoma and 14 control 
subjects) with strong reactivity against MCPyV w162 VP1 (  Figure 1  ) 
were tested for reactivity against each of the seven recombinant 
mutant VP1  –  GST fusion protein and wild-type VP1  –  GST fusion 
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  Figure 2    .        Correlation between reactivity 
against the major capsid protein (VP1) of 
Merkel cell polyomavirus (MCPyV) strain 
w162 and against VP1 proteins of the four 
other polyomaviruses: BK virus (BKV), JC 
virus (JCV), WU polyomavirus (WUPyV), 
and KI polyomavirus (KIPyV). Reactivity 
was determined in a multiplex antibody-
binding assay. Data are expressed as 
median ﬂ  uorescent intensity (MFI) for re-
activity against VP1 protein of the polyo-
maviruses as indicated from 76 control 
subjects from control group 1 and from 
41 case patients with Merkel cell carci-
noma. No distinctions were made 
between results from control subjects 
and from case patients, and each   dot   
represents one plasma sample.   Lines   = 
data from linear regression analyses. 
Correlation coefﬁ  cients  (  r   
2  ) are at the 
lower right corners.       jnci.oxfordjournals.org    JNCI | Articles 1517
proteins for both MCPyV strains w162 and 350. Reactivity against 
MCPyV fusion proteins, expressed as median fluorescent intensity, 
was normalized to reactivity against MCPyV w162 and an average 
normalized value was calculated for MCPyV 350 VP1 and each 
mutated VP1 fusion protein. Although binding of human antibodies 
to the recombinant VP1 proteins with a single mutation H288D or 
I316R was no greater than the binding to MCPyV 350 VP1, binding 
to the VP1 recombinant protein with two mutations H288D and 
I316R was indistinguishable from binding to MCPyV w162 VP1 
(  Figure 4, B  ). The N366D mutation did not affect antibody binding, 
either as a single mutation or in combination with other mutations. 
Similar levels of fusion protein expression were confirmed by use of 
an anti-Tag antibody (    Supplementary     Figure     2    , available online).                 
  Partial sequencing of the MCPyV VP1 open reading frame 
from DNA isolated from seven additional Merkel cell tumors 
showed that amino acids at positions 288, 316, and 366 in all seven 
VP1 sequences were identical with those in the VP1 sequences 
from viruses MCPyV w162 and MCPyV 339 (  Figure 4, C  ). Among 
the seven tumors, four had a glutamine at position 185 and three 
had an aspartate. It should be noted that the MCPyV VP1 from 
tumor 179 had a stop codon at position 123 (Genbank accession 
No. FJ649206). Thus, the nonconserved amino acids at positions 
288, 316, and 366 found in MCPyV strain 350 do not appear to be 
typical of MCPyV VP1 proteins found in tumors.   
    Quantitative Assessment of Anti-MCPyV Antibodies 
  To determine whether levels of antibodies against all five human 
polyomaviruses were different between antibody-positive case 
patients and antibody-positive control subjects and to explore 
potential cross-reactivity further, reactivity against VP1 proteins 
from all five polyomaviruses was determined in the plasma from 
the 24 subjects with the highest MCPyV w162 reactivity (12 case 
patients and 12 control subjects) by use of a quantitative antibody-
binding assay (  Figure 5  ). Levels of antibody against all VP1 fusion 
proteins were compared by use of their median EC  50   values, which 
are expressed as a dilution of the plasma. The case patients tended 
to have higher levels of anti-MCPyV VP1 antibodies (median 
EC  50   = dilution of 1:24    100) than the 12 control subjects (median 
EC  50   = dilution of 1:7457); however, this association did not 
achieve statistical significance (Mann  –  Whitney   P   = .31). When 
reactivity against MCPyV VP1 was compared with reactivity 
against the other polyomavirus VP1 proteins, we found that the 
level of antibodies against MCPyV was an order of magnitude 
higher than those of antibodies against the other four polyomavi-
rus VP1 proteins (eg, average EC  50   values for BKV: case patients = 
1:1470 and control subjects = 1:1170) (  Figure 5  ). This observation 
argues against the possibility that MCPyV reactivity resulted from 
cross-reactivity against other known polyomaviruses.           
    Prevalence of Antibodies Against Polyomaviruses in the 
General Population 
  To better understand the prevalence of antibodies to MCPyV and 
other polyomaviruses in individuals who do not have Merkel cell 
carcinoma, we tested serum from the 451 control subjects from the 
general population (control group 2) for reactivity against VP1 
proteins from MCPyV w162 and the other four polyomaviruses and 
for reactivity against the L1 protein from HPV-16. [The prevalence 
of L1 antibodies in these 451 subjects has been reported previously 
(  18  ).] Among these 451 control subjects, levels of antibodies against 
MCPyV VP1 fell into a distinctly bimodal distribution (  Figure 6  ). A 
cut point of 15    000 median fluorescent intensity units was chosen as 
described above and used to identify 268 (59.4%) of the 451 control 
subjects as seropositive for MCPyV VP1; this percentage was similar 
to that among women in control group 1 (ie, 53%). Among these 
451 control subjects, the prevalence of antibodies against VP1 
proteins from the other four types of human polyomaviruses was 413 
(92%, 95% CI = 89% to 94%) for BKV, 203 (45%, 95% CI = 40% 
to 50%) for JCV, 440 (98%, 95% CI = 96% to 99%) for WUPyV, 
and 406 (90%, 95% CI = 87% to 93%) for KIPyV (  Figure 7, A  ). 
When results from control group 2 (all women) were compared with 
results from the women in control group 1, only BKV prevalence 
was statistically significantly different (ie, in the control group 2, 413 
[92%, 95% CI = 89% to 94%] BKV-positive subjects of 451 control 
subjects, and in control group 1, 19 [79%, 95% CI = 58% to 93%] 
BKV-positive subjects of 24 control subjects;   P   = .02).                 
  Among the 47 control subjects in the youngest age group (ie, 
those aged 18  –  29 years) of control group 2, 26 (57%) were seropos-
itive for MCPyV w162 VP1 antibodies (  Figure 7, B  ). In addition, 
the percentage of MCPyV VP1 antibody  –  positive individuals did 
not vary by age group (  P    trend   = .6, comparing age groups in   Figure 7, 
B  ), indicating that most MCPyV w162 infections occurred before 
age 30 years. For HPV-16, the highest percentage of those seropos-
itive for HPV-16 L1 antibodies was observed in the youngest age 
group of women (42.6%) and the percentage declined with in-
creasing age (  P    trend   = .01, comparing age groups in   Figure 7, B  ); this 
pattern is consistent with the sexual transmission of HPV-16. For 
BKV, more women in the youngest age group (98%) than those in 
other age groups were positive for antibody against BKV VP1, and 
there was a statistically signiﬁ  cant decline in the percentage of BKV 
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    Figure 3    .       Quantitative multiplex binding assay. An antigen-coated bead 
mixture was incubated with serum that was highly reactive against the 
major capsid protein (VP1) from MCPyV strain w162 and other polyo-
maviruses. Before mixing with the antigen-coated beads, the serum 
was serially diluted 1:5, starting at a dilution of 1:100. Data are the me-
dian ﬂ  uorescent intensity (MFI) values, and the curves were generated 
by ﬁ  tting the data to a sigmoidal curve by use of the computer program 
GraphPad PRISM. BK virus (  solid squares  ), JC virus (  open triangles  ), 
WU polyomavirus (  open circles  ), KI polyomavirus (  open diamonds  ), 
Merkel cell polyomavirus strain w162 (  solid circles  ), and Merkel cell 
polyomavirus strain 350 (  open squares  ). The data are from a represen-
tative experiment of two experiments. Results of both experiments 
were similar.         1518   Articles | JNCI  Vol. 101, Issue 21  |  November 4, 2009
  Figure 4    .        Identiﬁ   cation of amino acid residues 
in the major capsid protein (VP1) of Merkel 
cell polyomavirus (MCPyV) 350 that confer low 
seroreactivity.   A  ) Alignment of VP1 sequences 
of three MCPyV strains and of the four other human 
polyomaviruses: BK virus (BKV), JC virus (JCV), KI 
polyomavirus (KIPyV), and WU polyomavirus 
(WUPyV). Sequences were obtained from GenBank 
and aligned with ClustalW (    http  ://  align  .  genome  .  jp  /  ). 
Sequences containing residues corresponding to 
the four divergent residues in the MCPyV VP1 
sequence are shown, with divergent residues 
boxed. Residue numbers refer to those in the 
MCPyV sequence. GenBank accession numbers for 
the VP1 sequences shown were FJ392560 for 
MCPyV w162, EU375803 for MCPyV 350, EU375804 
for MCPyV 339, NC_001538 for BKV, NC_001699 for 
JCV, EF127906 for KIPyV, and EF444549 for WUPyV. 
  B  ) Identiﬁ  cation of VP1 residues essential for anti-
body recognition of MCPyV strain w162. Point mu-
tations in the MCPyV 350 VP1 sequence and 
reactivity in plasma against the mutant proteins are 
shown. Point mutations at positions 288, 316, and 
366 were inserted in the MCPyV 350 VP1 sequence 
either alone or in combination by use of site- 
directed mutagenesis. All mutant proteins were 
expressed as GST  –  VP1 fusion proteins in bacteria 
and tested in a multiplex antibody-binding assay 
with 28 plasma samples that had been shown to 
have reactivity against MCPyV w162 VP1 (  Figure 1  ). 
The letters listed vertically on the   x  -axis are the one-
letter amino acid abbreviations for residues at the 
sequence position in the VP1 protein listed on the 
left. Letters that are   white   on a black background 
indicate that the sequence is the same as the 
MCPyV w162 VP1 sequence and letters that are 
  black   on a white background indicate that the 
sequence is the same as that of MCPyV 350 VP1. 
Data are the average median ﬂ  uorescent intensity 
(MFI) of the 28 plasma samples with reactivity 
against MCPyV w162 VP1 (one test per sample) 
after subtracting background and normalizing to the 
MFI for MCPyV w162.   Error bars   = 95% conﬁ  dence 
intervals. The data are from a representative exper-
iment of an experiment conducted twice.   C  ) 
Comparison of VP1 sequences from nine MCPyV 
strains. Partial sequences from seven Merkel cell 
tumors were compared with the full-length se-
quences of VP1 proteins from MCPyV strains w162 
and MCPyV350 (obtained from GenBank). Sequences 
around the nonconserved residues 185, 288, 316, 
and 366 are shown. Immunoreactive amino acids at 
positions 288 and 316 (  shaded  ) are conserved in all 
sequences except for that of MCPyV strain 350. The 
amino acid sequences were identical to those of 
strains w162 and 339 (data not shown), except for a 
D221N substitution at position 235 and a stop 
codon at position 123 in sequence 179 (GenBank 
accession numbers = FJ649201  –  FJ649207).       
VP1 antibody  –  positive women with increasing age (  P    trend   = .004; 
  Table 1  ). For JCV, there was a small but statistically signiﬁ  cant 
increase in the percentage of JCV antibody  –  positive women with 
increasing age (  P    trend   = .04). No associations were found between 
carrying antibody against WUPyV or KIPyV and increasing age, 
indicating that most of those infections also occurred during child-
hood. In addition, antibody against VP1 proteins from WUPyV or 
KIPyV persisted until at least age 70 years. 
  Among women in control group 2, MCPyV w162 antibody 
positivity was not associated with the lifetime number of sexual 
partners (  P   = .2) (  Figure 7, C  ), supporting a nonsexual route of 
transmission. As expected for the sexual transmission of HPV-16, 
we observed a strong association between the lifetime number of 
sex partners and antibody positivity for HPV-16 (  P   < .001). In 
addition, antibody positivity against any of the other four human 
polyomaviruses was not associated with the number of sex partners 
(data not shown).     
    Discussion 
  We found that antibodies specific for MCPyV were detected in 
statistically significantly more case patients with Merkel cell 
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carcinoma than control subjects. This association was found to 
be specific for MCPyV and not due to the presence of cross- 
reactive antibodies against other polyomaviruses. These findings 
support a role for MCPyV in the etiology of this rare skin carci-
noma. However, exposure to MCPyV, as measured by the pres-
ence of antibodies, like exposure to the other known human 
polyomaviruses, was found to be common in the general popula-
tion. The high concentration of antibodies against MCPyV 
suggests that there may be a viremic or systemic stage of MCPyV 
infection as described for BKV or JCV (  26  ). This result is in 
contrast with the low concentrations of antibodies against papil-
lomaviruses whose infections are restricted to the epithelium. 
  Also similar to other polyomaviruses, infection with MCPyV 
occurred before young adulthood, and the prevalence was stable at 
older ages. We have not had an opportunity to examine serum 
from children to pinpoint the age of infection more precisely, but 
we have found that seropositivity was not more common in young 
adults than in older adults or in those with a higher numbers of sex 
partners than in those with a lower number. 
  Evidence for the speciﬁ  city of these antibody-binding assays was 
based on the following observations: 1) No association was observed 
between seropositivity to MCPyV and to any other polyomavirus. 
2) Patterns of responses to the polyomavirus VP1s varied greatly 
between subjects. 3) High levels of MCPyV antibodies did not 
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  Figure 5    .        Quantitative measurement of anti-
bodies against the major capsid protein (VP1) 
of human polyomaviruses. A quantitative mul-
tiplex antibody-binding assay was used to 
measure antibodies in plasma from case 
patients with Merkel cell carcinoma and con-
trol subjects (control group 1) who had tested 
strongly positive in the multiplex antibody-
binding assay ( Figure 1 ). Plasma (or hybridoma 
supernatant) was diluted to 1:333 followed by 
eight 1:3 serial dilutions (with the highest dilu-
tion = 1:7.29 × 10 
5  ) and tested for reactivity 
against VP1 proteins from the following polyo-
maviruses: BK virus, JC virus, WU polyomavi-
rus, KI polyomavirus, and Merkel cell carcinoma 
polyomavirus virus (MCPyV). Data from one 
representative case patient with Merkel cell 
carcinoma or one representative control sub-
ject are shown in each panel. Data from other 
subjects were similar. Data points are the me-
dian ﬂ   uorescent intensities (MFIs) for each 
antigen, which is a relative measure of the 
amount of human IgG bound to the fusion 
proteins. Curves were generated (and the anti-
body dilution producing one-half of the maxi-
mal binding [EC  50   value] was calculated) by 
ﬁ  tting the data to an equation for a sigmodal 
curve. The plasma samples used in this experi-
ment had been identiﬁ  ed previously as having 
high reactivity against the VP1 of MCPyV 
w162. The data are from a representative ex-
periment of two experiments. Results of both 
experiments were similar.       1520   Articles | JNCI  Vol. 101, Issue 21  |  November 4, 2009
correlate with high levels of antibodies against VP1s from other 
polyomaviruses. 4) Antibody positivity to MCPyV but not the other 
polyomaviruses was strongly associated with Merkel cell 
carcinoma. 
  The higher antibody prevalence among case patients with 
Merkel cell carcinoma is consistent with the hypothesis that 
MCPyV plays a role in the development of Merkel cell carci-
noma. The lack of association between Merkel cell carcinoma 
and antibody positivity to the other polyomaviruses indicates that 
these patients are not globally susceptible to polyomavirus infec-
tion or reactivation. Although immunosuppression has been as-
sociated with Merkel cell carcinoma (  2  ) and immunosuppression 
often leads to reactivation of polyomaviruses, higher levels of 
antibody positivity against other polyomaviruses were not 
observed. 
  Studies (  3  ,  24  ,  27  ,  28  ) that have tested for the MCPyV genome 
in Merkel cell carcinoma have found that between 15% and 30% 
of the tumors had no detectable viral DNA. Indeed, in this study, 
we detected MCPyV DNA in 24 (77%) of 31 case patients. 
Intriguingly, all seven case patients with Merkel cell carcinoma 
whose tumors were negative for MCPyV DNA had plasma that 
was positive for MCPyV VP1 antibodies. This result raises the 
possibility that MCPyV plays a role in cancer initiation but is not 
required for maintenance of the tumorigenic phenotype in all 
case patients and may be one explanation as to why some Merkel 
cell carcinomas are negative for MCPyV DNA. Alternatively, 
because MCPyV infections are common, there may be MCPyV-
independent pathways that lead to Merkel cell carcinoma. 
  MCPyV has been shown to be integrated into the DNA of 
some Merkel cell carcinoma tumors (  3  ), analogous to the manner 
in which high-risk HPV DNA is integrated into the DNA of 
cervical cancers (  29  ). However, because some Merkel cell carci-
nomas do not appear to contain MCPyV DNA and other Merkel 
cell carcinoma tumors contain much less than one viral genome 
per cell, the role that this virus plays in cancer development 
might be quite different from that of HPV in the development 
of cervical cancer (  30  ). Another apparent difference in the devel-
opment of these cancers is the longer time interval between 
initial exposure to MCPyV (before age 30 years) and develop-
ment of Merkel cell carcinoma (median age = 70 years). For 
cervical cancer, the interval is approximately 30 years (eg, from 
HPV infection at age 20 years to diagnosis of cervical cancer at 
age 50 years) (  31  ). The long time interval for the development 
of Merkel cell carcinoma suggests that rare genetic event(s) 
might be occurring in addition to the common event of MCPyV 
infection (  32  ). 
  We have previously shown that a higher proportion of 
patients with Merkel cell carcinoma from North America than 
from Australia were positive for MCPyV DNA (  24  ). This differ-
ence may be due to differences in sun exposure, the presence of 
an undetectable MCPyV strain, or heterogeneous distributions 
of MCPyV worldwide. Future studies should examine the prev-
alence of MCPyV antibodies in different geographic popula-
tions. Furthermore, if the ﬁ  ndings in our study are similar to 
those of other case  –  control studies, a prospective study with 
samples collected before diagnosis of Merkel cell carcinoma 
would be an important step to establishing causality. In this 
study, samples from case patients were collected after diagnosis 
of Merkel cell carcinoma, so the disease process may have had 
an impact on the antibody level. However, this study was 
matched on sex and age, which reduces possible confounding by 
these factors. 
  In comparison to the results from MCPyV strain w162, only 
two of 41 case patients had detectable levels of antibodies against 
MCPyV strain 350. By mutating each of three discordant resi-
dues in the VP1 sequence for MCPyV strain 350 (residues 288, 
316, and 366) to those of strain w162, alone or in combination, 
we found that both residues 288 and 316 were required to confer 
MCPyV w162  –  like binding by human serum to the strain 350 
VP1 sequence. It is likely that these two mutations altered the 
folding of VP1 from MCPyV 350 to ablate the formation of 
conformation-dependent epitopes recognized by human serum, 
but it was not possible to determine whether MCPyV-speciﬁ  c 
antibodies recognize only native VP1 protein because denatured 
GST  –  VP1 fusion proteins did not bind to the polystyrene beads 
(results not shown). Sequences of the open reading frames of 
MCPyV VP1 from seven additional tumors were all identical 
with VP1 proteins from MCPyV strains 339 and w162 at posi-
tions 288, 316, and 366 (position 185 was either glutamine or 
glutamic acid). This ﬁ  nding is reminiscent of the ﬁ  rst cloned 
HPV-16 L1 sequence from a cervical cancer, which had a non-
conservative mutation that inhibited capsid assembly and binding 
by antibodies against L1 that were speciﬁ  c  to  conformation- 
dependent epitopes (  33  ). 
  This is the ﬁ  rst study, to our knowledge, to test for antibodies 
against all ﬁ  ve polyomaviruses simultaneously. The prevalence of 
antibodies against BKV and JCV, which we reported, is consis-
tent with previous observations (  10  ,  13  ,  34  ). A previous study (  34  ) 
reported that the prevalence of BKV decreased with increasing 
age and that JCV antibody prevalence peaked at approximately 
age 60 years. Approximately 90% of people in our control groups 
were positive for antibody against WUPyV and/or KIPyV, the 
two polyomaviruses that were recently discovered in respiratory 
infections (  8  ,  9  ). The prevalence of antibodies against these 
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    Figure 6    .       Distribution of seroreactivity against the major capsid proteins 
(VP1) of all ﬁ  ve human polyomavirus (BK virus [BKV], JC virus [JCV], 
WU polyomavirus [WUPyV], KI polyomavirus [KIPyV], and Merkel cell 
carcinoma polyomavirus virus [MCPyV]) and human papillomavirus 
(HPV) 16 L1 protein among 451 women in population-based control 
group 2. The multiplex antibody-binding assay was used to assess 
seroreactivity in 451 samples previously tested for HPV-16 L1 reactivity 
(  18  ). The background median ﬂ  uorescent intensity (MFI) values were 
subtracted from MFI values for each VP1 and for HPV-16 L1 and data 
were plotted.   Dotted lines   indicate the cut points of 15    000 for polyoma-
viruses and of 820.25 for the HPV-16 L1. The HPV-16 L1 cut point was 
the highest quartile of values.         jnci.oxfordjournals.org    JNCI | Articles 1521
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    Figure 7    .       Association of seropositivity against the major capsid protein 
(VP1) from Merkel cell polyomavirus (MCPyV) w162 or L1 protein from 
human papillomavirus 16 (HPV-16) with age or number of sexual part-
ners.   A  ) Percentage of women in the general population who are sero-
positive for polyomaviruses. Reactivity against the major capsid proteins 
(VP1) of the ﬁ  ve human polyomaviruses (BK virus [BKV], JC virus [JCV], 
WU polyomavirus [WUPyV], KI polyomavirus [KIPyV], and Merkel cell 
carcinoma polyomavirus virus [MCPyV]) and HPV-16 L1 protein was 
assessed in serum from 451 control subjects (in the population-based 
control group 2) by use of the multiplex antibody-binding assay. Data are 
the proportion of seropositive samples for each polyomavirus type 
tested.   Error bars   = 95% conﬁ  dence intervals (CIs).   B  ) Association of 
MCPyV and HPV-16 seropositivity with age. Age-stratiﬁ  ed seropositivity 
for HPV-16 (  lightly shaded bars  ) and MCPyV w162 (  solid bars  ). The fol-
lowing numbers of serum were evaluated in each group: 47 in the age 
group of 18  –  29 years (MCPyV seropositivity = 55.3%, 95% CI = 40.1% to 
69.8%; HPV-16 seropositivity = 42.6%, 95% CI = 28.3% to 57.8%), 122 in 
the age group of 30  –  39 years (MCPyV = 55.7%, 95% CI = 46.5% to 64.7%; 
HPV-16 = 26.2%, 95% CI = 18.7% to 35.0%), 119 in the age group of 40  –  49 
years (MCPyV = 64.7%, 95% CI = 55.4% to 73.2%; HPV-16 = 26.9%, 95% 
CI = 19.2% to 35.8%), 83 in the age group of 50  –  59 years (MCPyV = 59.0%, 
polyomaviruses was not statistically signiﬁ  cantly different in the 
age groups tested. Future prospective studies should examine 
serum from younger populations to determine the time most 
people become infected with MCPyV and the other newly iden-
tiﬁ  ed polyomaviruses. 
  This study had several limitations, including retrospective 
enrollment of case patients and control subjects. A long-term 
prospective study that could track antibody response to the virus 
and cancer development as they develop over time would theo-
retically be ideal. In such a study, the numbers of case patients 
with Merkel cell carcinoma among those exposed and unexposed 
to the virus could directly be compared. However, given the 
high prevalence of MCPyV antibodies starting at young ages 
and the rarity of the cancer outcome among older adults, this 
ideal study would be inefﬁ  cient. The efﬁ  cient case  –  control study 
design that we used and the strong risk of Merkel cell carcinoma 
that we found to be associated with MCPyV support the expec-
tation that these ﬁ   ndings are likely to be accurate. Another 
potential limitation is that the study subjects were primarily 
white, which might constrain how widely these results can be 
generalized. However, in US Surveillance, Epidemiology, and 
End Results data, more than 95% of Merkel cell carcinomas 
were reported in white patients (  35  ). Another limitation of this 
study was lack of gold standards for MCPyV antibody positivity 
and negativity. Any nondifferential misclassiﬁ  cation would tend 
to reduce the association; therefore, the robust association 
observed here between MCPyV w162 antibody reactivity and 
Merkel cell carcinoma supports the likelihood of the principal 
ﬁ  ndings of this study. 
  We conclude that MCPyV is a relatively common infection but 
the higher prevalence among case patients compared with control 
subjects is consistent with the hypothesis that this virus has a role 
in the development of Merkel cell carcinoma. It should be 
remembered that Merkel cell cancer is rare, with an age-adjusted 
incidence rate of 0.44 per 100    000 individuals (  36  ). Thus, although 
antibody reactivity against MCPyV was associated with an 
increased risk of developing Merkel cell cancer, the absolute risk 
of cancer development in MCPyV antibody  –  positive individuals is 
exceeding low.   
95% CI = 47.7% to 69.7%; HPV-16 = 16.7%, 95% CI = 9.5% to 26.7%), 46 in 
the age group of 60  –  69 years (MCPyV = 65.2%, 95% CI = 49.8% to 78.6%; 
HPV-16 = 21.7%, 95% CI = 10.9% to 36.4%), and 33 in the age group of 
70  –  74 years (MCPyV = 51.5%, 95% CI = 33.5% to 69.2%; HPV-16 = 12.1%, 
95% CI = 3.4% to 28.2%). For the association between seropositivity for 
HPV-16 L1 and age,   P    trend   = .002. For the association between seroposi-
tivity for MCPyV and age,   P    trend   = .6.   C  ) Association of MCPyV and HPV-16 
seropositivity with number of sex partners.   Lightly shaded   = seroposi-
tivity against HPV-16 L1,   solid bars   = MCPyV w162 VP1. The following 
numbers of serum samples were evaluated in each group: 123 in the one-
partner group (MCPyV seropositivity = 55.7%, 95% CI = 46.5% to 64.7%; 
HPV-16 seropositivity = 14.8%, 95% CI = 9.0% to 22.3%), 131 in the two- or 
three-partner group (MCPyV = 61.8%, 95% CI = 52.9% to 70.2%; HPV-16 = 
18.3%, 95% CI = 12.1% to 26.0%), 151 in the ﬁ  ve- to 14-partner group 
(MCPyV = 57.6%, 95% CI = 49.3.5% to 65.6%; HPV-16 = 36.4%, 95% CI = 
28.8% to 44.6%), and 38 in the group with 15 or more partners (MCPyV = 
68.4%, 95% CI = 51.3% to 82.5%; HPV-16 = 39.5%, 95% CI = 24.0% to 
56.6%). For the association between seropositivity against HPV-16 L1 and 
number of sex partners,   P    trend   < .001. For the association between sero-
positivity against MCPyV VP1 and number of sex partners,   P    trend   = .5.         1522   Articles | JNCI  Vol. 101, Issue 21  |  November 4, 2009
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